Isar-Test Investigators
5 Papers
Isar-Test Investigators is an academic researcher. The author has contributed to research in topics: Drug-eluting stent & Restenosis. The author has an hindex of 5, co-authored 5 publications.
Chat about Author
Papers
2-Year Clinical and Angiographic Outcomes From a Randomized Trial of Polymer-Free Dual Drug-Eluting Stents Versus Polymer-Based Cypher and Endeavor, Drug-Eluting Stents
Robert A. Byrne,Adnan Kastrati,Klaus Tiroch,Stefanie Schulz,Jürgen Pache,Susanne Pinieck,Steffen Massberg,Melchior Seyfarth,Karl-Ludwig Laugwitz,Katrin A. Birkmeier,Albert Schömig,Julinda Mehilli,Isar-Test Investigators +12 more
TL;DR: The antirestenotic efficacy of both Dual- DES and ZES remained durable between 1 and 2 years, with Dual-DES maintaining an advantage over the entire 2-year period, and there was no signal of a differential safety profile between the 3 stent platforms.
122
Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results
Robert A. Byrne,Sebastian Kufner,Klaus Tiroch,Steffen Massberg,K L Laugwitz,Birkmeier A,S. Schulz,Julinda Mehilli,Isar-Test Investigators +8 more
TL;DR: Clinical antirestenotic efficacy was maintained with all three platforms between 1 and 2 years, although angiographic surveillance showed ongoing delayed LLL with both BP and PP stent platforms, and at 2 years there was no signal of a differential safety profile.
99
10-Year Outcomes From a Randomized Trial of Polymer-Free Versus Durable Polymer Drug-Eluting Coronary Stents
Sebastian Kufner,Maximilian Ernst,Salvatore Cassese,Michael Joner,Katharina Mayer,Roisin Colleran,Tobias Koppara,Erion Xhepa,Tobias Koch,Jens Wiebe,Tareq Ibrahim,Massimiliano Fusaro,Karl-Ludwig Laugwitz,Heribert Schunkert,Adnan Kastrati,Robert A. Byrne,Isar-Test Investigators +16 more
TL;DR: At 10 years, there were no measurable differences in outcomes between patients treated with polymer-free versus durable polymer DES, and the incidence of stent thrombosis was low and comparable in both groups.
73
Randomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents: 5-Year Results of the ISAR-TEST-5 Trial.
Sebastian Kufner,Jonas Sorges,Julinda Mehilli,Salvatore Cassese,Janika Repp,Jens Wiebe,Raphaela Lohaus,Annalena Lahmann,Tobias Rheude,Tareq Ibrahim,Steffen Massberg,Karl L. Laugwitz,Adnan Kastrati,Robert A. Byrne,Isar-Test Investigators +14 more
TL;DR: Long-term outcomes of patients treated with polymer-free sirolimus- and probucol-Eluting stents compared with a new-generation durable polymer-based zotarolimus-eluting stent were similar, and rates of stent thrombosis were low and comparable in both treatment groups, with few events beyond 12 months.
64
Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial.
Robert A. Byrne,Adnan Kastrati,Steffen Massberg,Anna Wieczorek,Karl-Ludwig Laugwitz,Martin Hadamitzky,Stefanie Schulz,Jürgen Pache,Massimiliano Fusaro,Jörg Hausleiter,Albert Schömig,Julinda Mehilli,Isar-Test Investigators +12 more
TL;DR: Biodegradable polymer and permanent polymer DES are associated with similar clinical outcomes at 3 years and EES are comparable to SES in terms of overall clinical efficacy and safety.